Table 1. Summary of patient characteristics at the time of kidney transplantation (n = 805) and details concerning immunosuppressive treatments and acute rejection.
| Male (%)/Female (%) | 492 (61.1)/313 (38.9) |
| Age at transplantation (years) | 51.0 [18.0–83.0] |
| Primary kidney disease (%) | |
| • Glomerulonephritis | 33.9 |
| • Diabetic nephropathy | 9.3 |
| • Interstitial nephropathy | 36.4 |
| • Vascular nephropathy | 7.6 |
| • Other/unknown | 12.8 |
| Dialysis duration (months) | 33 [0–452] |
| HD/PD/preemptive transplantation (%) | 70.6/19.2/10.2 |
| Transplantation rank ≥ 2 (%) | 22.9 |
| Pre-transplant corticotherapy, n = 419 (%) | 59.6 |
| Body mass index (kg/m2) | 24.7 [13.6–39.1] |
| Pre-transplant diabetes Type 1/Type 2 | 1.4/23.9 |
| Dyslipidemia, n = 758 (%) | 50.4 |
| Current or former smoker, n = 274 (%) | 59.9 |
| Pre-transplant BMD status, n = 707 (%): | |
| • Normal/osteopenia/osteoporosis | 31.3/45.8/22.9 |
| Immunosuppressive treatments | |
| • Anti-IL2 receptor antibody/Thymoglobulin (%) | 36.7/58.3 |
| • Cyclosporin A/Tacrolimus/mTOR inhibitor (%) | 60.7/38.5/1.2 |
| • Total (oral + bolus) corticosteroid dose at M3 (mg) | 2075 [500–4790] |
| • Total (oral + bolus) corticosteroid dose at M12 (mg) | 2978 [500–9855] |
| Delayed graft function (%) | 28.5 |
| Acute rejection | |
| • Cumulative incidence at M3/M12/M24 (%) | 7.7/16.2/19.8 |
| • Pure TCMR/pure ABMR/mixed (%) | 14.9/2.2/2.5 |
Data are given as percentages or medians [minimum–maximum], as appropriate. HD, hemodialysis; PD, peritoneal dialysis; BMD: bone mineral density; mTOR, mammalian target of rapamycin; n, number of analyzed patients; TCMR, T cell-mediated rejection; ABMR, antibody-mediated rejection.